Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly Q3 earnings and revenue top estimates, boosted by weight loss drug demand
09:58am, Thursday, 30'th Oct 2025
Eli Lilly and Co (NYSE:LLY) on Thursday reported third quarter 2025 financial results that handily beat Wall Street forecasts, as the company continued to see strong demand for its weight loss dru
Eli Lilly Blows Away Q3 Earnings Expectations
09:25am, Thursday, 30'th Oct 2025
Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year guidance.
Eli Lilly shares jump as blowout earnings, obesity drug demand fuel profit upgrade
09:12am, Thursday, 30'th Oct 2025
Shares of Eli Lilly rose nearly 4% in premarket trading on Thursday after the pharmaceutical company reported third-quarter earnings that exceeded expectations and lifted its annual profit forecast. T
20% Upside For Eli Lilly Stock?
09:05am, Thursday, 30'th Oct 2025
Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli Lilly recently announced a significant partnership with Walmart to sell its po
Eli Lilly (LLY) Q3 Earnings and Revenues Surpass Estimates
08:55am, Thursday, 30'th Oct 2025
Eli Lilly (LLY) came out with quarterly earnings of $7.02 per share, beating the Zacks Consensus Estimate of $6.02 per share. This compares to earnings of $1.18 per share a year ago.
5 Things to Know Before the Stock Market Opens
08:50am, Thursday, 30'th Oct 2025
Stock futures are losing ground amid a barrage of earnings reports from major companies, as investors assess the latest developments in trade talks and Federal Reserve Chair Jerome Powell's warning th
Eli Lilly's stock jumps as Zepbound sales nearly triple at lower prices
08:09am, Thursday, 30'th Oct 2025
Eli Lilly's stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
06:45am, Thursday, 30'th Oct 2025
Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported basis and increased by $5.84 to $7.02 on a
Pharmaceutical Stocks To Keep An Eye On – October 28th
02:09am, Thursday, 30'th Oct 2025
Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, Pfizer, Incyte, AbbVie, and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock
Top Medical Stocks To Research – October 28th
02:09am, Thursday, 30'th Oct 2025
UnitedHealth Group, Avidity Biosciences, Eli Lilly and Company, Regeneron Pharmaceuticals, and Johnson and Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener
Eli Lilly Reports Earnings Thursday as Investors Await Trump Drug Pricing Deal
04:45pm, Wednesday, 29'th Oct 2025
The drugmaker Eli Lilly reports its third-quarter results early Thursday, as questions loom about what kind of deal it will reach with the Trump administration over the price of its weight-loss drug.
Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound
02:19pm, Wednesday, 29'th Oct 2025
Eli Lilly and Walmart said they have teamed up to boost access to the pharma giant's weight loss drug Zepbound, allowing U.S. patients to access vials of the blockbuster injection at direct-to-consume
Eli Lilly to invest $1.2 billion in Puerto Rico as part of US manufacturing push
10:33am, Wednesday, 29'th Oct 2025
Eli Lilly said on Wednesday it will invest more than $1.2 billion to expand its manufacturing site in Puerto Rico, as the drugmaker looks to increase its U.S. production capacity to hedge against pote
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
10:30am, Wednesday, 29'th Oct 2025
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs INDIANAPOLIS , Oct. 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today a planned investment of
In Lilly vs Novo obesity drug battle, Trump price talks grab focus
10:06am, Wednesday, 29'th Oct 2025
As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release results for the third quarter, investors are looking elsewhere: high-stakes price talks with U.S. President Donald Trump.
